Kaerus Bioscience has received US Food and Drug Administration’s (FDA) designations for KER-0193 to treat Fragile X syndrome ...

A new specialist manufacturing facility in Scotland could soon provide solutions to scaling challenges for vital ...

Boehringer Ingelheim has entered a multi-year partnership with Tempus AI to progress its cancer treatment pipeline.

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

Recipharm has joined forces with ProductLife Group (PLG) to support (bio)pharmaceutical firms in expediting market approval ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Eligo Bioscience has secured a $5m grant from the French Government to expedite the development of its topical gene delivery ...

Japan’s MHLW has approved Sarepta Therapeutics’ gene therapy Elevidys for treating Duchenne muscular dystrophy (DMD) ...

The UK MHRA has approved AstraZeneca's Trixeo Aerosphere inhaler to treat adults with chronic obstructive pulmonary disease ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

Abeona’s deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.

US President Donald Trump has signed an executive order telling drugmakers to cut prices to 'most favoured nation' pricing.